South Korea-based DI Biotech negotiated a license to market and provide full product support for Gyros’ automated microimmunoassay platform, Gyrolab®, in the Korean life science market.
Gyrolab is a bioanalytical, automated microlaboratory system that Gyros claims addresses critical needs in therapeutic protein development, from early screening to the completion of clinical trials. The technology has been designed to miniaturize and integrate assay steps for protein quantification immunoassays and is reportedly compatible with any immunoassay design.
According to S. E. Kim, president and CEO at DI Biotech, the region’s pharma and biotech companies, along with its CROs and CMOs, believe the technology will “not only ramp-up productivity but also boost their competitiveness. We have already tested the market for Gyrolab in Korea, and the response was immediate and positive. The financial standing of these industries was already strong and coupled with the Korean government’s recent investment of the equivalent of €90 million to further propel the development of biotherapeutics within the SMART project, we are extremely optimistic about the rapid uptake and implementation of Gyrolab in Korea.”
In June Gyros completed an approximately €7.5 million round of equity financing to help drive further commercialization of Gyrolab technology. At the time, the company said it already had an installed base of about 40 systems, at companies including Merck, Medimmune, GSK, Amgen, Pfizer, Ablynx, and ThromboGenics.
In April MedImmune purchased its fifth Gyrolab system. Also in April Gyros launched Gyrolab xP, a second-generation system. The company claims the new system is easier to use and features 21 CFR part 11 compliance and extended validation support for implementation in GLP-regulated environments.